Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
September 11, 2020– Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations – – Time Course of MRI Lesion Suppression Shows…Immunic, Inc. to Participate in Scientific and Investor Conferences in September
September 8, 2020NEW YORK, September 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
August 20, 2020NEW YORK, August 20, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 10, 2020NEW YORK, August 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral…Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
August 5, 2020NEW YORK, August 4, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
August 3, 2020NEW YORK, August 3, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed…Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
August 2, 2020– Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis –…Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020NEW YORK, July 30, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. to Participate in Investor Conferences in August
July 29, 2020NEW YORK, July 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19
July 27, 2020– Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust – NEW YORK, July 27, 2020 – Immunic,…